Research programme: heart disorder therapies - Forcefield Therapeutics
Latest Information Update: 23 Dec 2022
At a glance
- Originator Forcefield Therapeutics
- Class Heart failure therapies; Proteins
- Mechanism of Action Cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myocardial infarction